Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
ARS Pharmaceuticals Inc has a consensus price target of $23.6 based on the ratings of 6 analysts. The high is $30 issued by Cantor Fitzgerald on October 8, 2024. The low is $14 issued by SVB Leerink on December 13, 2022. The 3 most-recent analyst ratings were released by Raymond James, Leerink Partners, and Cantor Fitzgerald on January 14, 2025, January 13, 2025, and October 8, 2024, respectively. With an average price target of $28.33 between Raymond James, Leerink Partners, and Cantor Fitzgerald, there's an implied 176.69% upside for ARS Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for ARS Pharmaceuticals (NASDAQ:SPRY) was reported by Raymond James on January 14, 2025. The analyst firm set a price target for $28.00 expecting SPRY to rise to within 12 months (a possible 173.44% upside). 11 analyst firms have reported ratings in the last year.
The latest analyst rating for ARS Pharmaceuticals (NASDAQ:SPRY) was provided by Raymond James, and ARS Pharmaceuticals maintained their strong buy rating.
The last upgrade for ARS Pharmaceuticals Inc happened on August 13, 2024 when Raymond James raised their price target to $22. Raymond James previously had an outperform for ARS Pharmaceuticals Inc.
The last downgrade for ARS Pharmaceuticals Inc happened on September 20, 2023 when William Blair changed their price target from N/A to N/A for ARS Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ARS Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ARS Pharmaceuticals was filed on January 14, 2025 so you should expect the next rating to be made available sometime around January 14, 2026.
While ratings are subjective and will change, the latest ARS Pharmaceuticals (SPRY) rating was a maintained with a price target of $26.00 to $28.00. The current price ARS Pharmaceuticals (SPRY) is trading at is $10.24, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.